Literature DB >> 11702827

Plasma elimination of cardiac troponin I in end-stage renal disease.

K Ellis1, A W Dreisbach, J L Lertora.   

Abstract

BACKGROUND: We retrospectively compared the decline of cardiac troponin I after acute myocardial infarction (AMI) in patients with normal renal function and those with end-stage renal disease (ESRD) who were receiving hemodialysis.
METHODS: We reviewed 257 cases with a discharge diagnosis of AMI or AMI plus ESRD; 222 were excluded due to inadequate data or evidence of ongoing myocardial necrosis. Decline of cardiac troponin I values was followed over a mean (+/- SD) of 2.75 +/- 1.2 days in patients with normal renal function and 2.7 +/- 2.0 days in ESRD patients. Average apparent half-life and apparent elimination rate constant of troponin I were compared between groups.
RESULTS: Of 35 patients with AMI, 16 had ESRD and were receiving hemodialysis, and 19 had normal renal function. Mean (+/- SD) apparent half-lives of troponin I in the ESRD group and the group with normal renal function were 1.48 +/- 0.77 days and 1.08 +/- 0.63 days, respectively. The mean apparent elimination rate constants of cardiac troponin I were 0.64 +/- 0.33 days(-1) in the ESRD group and 0.91 +/- 0.55 days(-1) in the group with normal renal function.
CONCLUSION: The difference in apparent half-life and apparent elimination rate constant of cardiac troponin I between patients with normal renal function and those with ESRD is not statistically significant.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11702827

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  23 in total

Review 1.  Cardiac enzymes, renal failure and renal transplantation.

Authors:  Huseyin Bozbas; Aylin Yildirir; Haldun Muderrisoglu
Journal:  Clin Med Res       Date:  2006-03

2.  What Is the Meaning of Increased Myocardial Injury Enzymes during Hemodialysis? A Tissue Doppler Imaging Study.

Authors:  Gürsel Yildiz; Mansur Kayataş; Ferhan Candan; Mehmet Birhan Yilmaz; Ali Zorlu; Savaş Sarikaya
Journal:  Cardiorenal Med       Date:  2013-06-25       Impact factor: 2.041

3.  Biomarkers and cardiac disease in patients with end-stage renal disease on dialysis.

Authors:  Peter E Hickman
Journal:  Clin Biochem Rev       Date:  2011-05

4.  High-sensitive troponin T increase after hemodialysis is associated with left ventricular global longitudinal strain and ultrafiltration rate.

Authors:  Serkan Ünlü; Asife Şahinarslan; Burak Sezenöz; Orhan Mecit Uludağ; Gökhan Gökalp; Özden Seçkin; Selim Turgay Arınsoy; Özlem Gülbahar; Nuri Bülent Boyacı
Journal:  Cardiol J       Date:  2018-10-19       Impact factor: 2.737

5.  High sensitive TROponin levels In Patients with Chest pain and kidney disease: A multicenter registry - The TROPIC study.

Authors:  Flavia Ballocca; Fabrizio D'Ascenzo; Claudio Moretti; Roberto Diletti; Carlo Budano; Alberto Palazzuoli; Matthew J Reed; Tullio Palmerini; Dariusz Dudek; Alfredo Galassi; Pierluigi Omedè; Nicolas M Mieghem; David Ferenbach; Marco Pavani; Diego Della Riva; Nick L Mills; Ron T Van Domburgh; Andrea Mariani; Artur Dziewierz; Marco di Cuia; Robert Jan van Geuns; Felix Zijlstra; Serena Bergerone; Sebastiano Marra; Giuseppe Biondi Zoccai; Fiorenzo Gaita
Journal:  Cardiol J       Date:  2017-03-10       Impact factor: 2.737

6.  Histamine blood concentration in ischemic heart disease patients.

Authors:  Vladimir Zdravkovic; Suzana Pantovic; Gvozden Rosic; Aleksandra Tomic-Lucic; Nemanja Zdravkovic; Maja Colic; Zdravko Obradovic; Mirko Rosic
Journal:  J Biomed Biotechnol       Date:  2011-06-06

Review 7.  Metabolic Pathway of Cardiospecific Troponins: From Fundamental Aspects to Diagnostic Role (Comprehensive Review).

Authors:  Aleksey M Chaulin
Journal:  Front Mol Biosci       Date:  2022-04-19

Review 8.  Cardiac Troponins in Dogs and Cats.

Authors:  R Langhorn; J L Willesen
Journal:  J Vet Intern Med       Date:  2015-12-17       Impact factor: 3.333

9.  Sensitive troponins--which suits better for hemodialysis patients? Associated factors and prediction of mortality.

Authors:  Ferruh Artunc; Christian Mueller; Tobias Breidthardt; Raphael Twerenbold; Andreas Peter; Claus Thamer; Peter Weyrich; Hans-Ulrich Haering; Bjoern Friedrich
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

10.  Increased Circulating Advanced Oxidation Protein Products and High-Sensitive Troponin T in Cirrhotic Patients with Chronic Hepatitis C: A Preliminary Report.

Authors:  Jolanta Zuwala-Jagiello; Eugenia Murawska-Cialowicz; Monika Pazgan-Simon
Journal:  Biomed Res Int       Date:  2015-11-19       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.